2014 | Medical Innovation Summit

Now, it's Personal

Cancer Treatment and Personalized Medicine October 27-29, 2014 Cleveland, Ohio

 
  • Download Our FREE Mobile App

    Stay connected. Download today!

    appleStore.pnggooglePlay.png
  • 2014 Summit Preview

    Join more than 1,500 senior executives, investors, entrepreneurs and clinicians who will gather in Cleveland to discuss investable innovations that can lead to the detection and treatment of cancer. The 2014 Summit will include:
     

    • Detailed insights into the latest breakthroughs of personalized medicine
    • Discussions with world leaders responsible for the change in healthcare technology.
    • Top 10 Medical Innovations for 2015
       

2013 Speakers

| View All Speakers

José E. Almeida

CEO, Covidien

José E. Almeida | CEO, Covidien ,

José E. Almeida has been the President, Chief Executive Officer and a Director of Covidien since July 2011. Mr. Almeida became Chairman of the Board of Directors in March 2012. Prior to being elected President and Chief Executive Officer, Mr. Almeida was President of the Medical Devices segment of Covidien. In this position, Mr. Almeida oversaw the Surgical Devices, Energy-based Devices, Respiratory & Monitoring Solutions and Vascular Therapies Global Business Units, as well as the Japan, Asia, Canada and Latin America regions. These businesses account for approximately two-thirds of the Company’s total annual revenues and about three-quarters of its operating profit.

Mr. Almeida joined Covidien in 1995 as Director of Manufacturing and Corporate Engineering, and then held several positions of increasing responsibility, including Vice President of European Manufacturing and Vice President of Global Manufacturing. Mr. Almeida left in 2003 for Greatbatch Technologies, Inc., a leading manufacturer of power sources and components for implantable medical devices, before returning to Covidien in 2004 as President of the International Business Unit.

Before joining Covidien, Mr. Almeida was a Director of Manufacturing in American Home Products’ Acufex Microsurgical division, an Engineering Manager of Johnson & Johnson’s Professional Products division and a Management Consultant at Andersen Consulting (Accenture). Mr. Almeida received a Bachelor’s degree from Escola de Engenharia Maua in São Paulo, Brazil. He currently serves on the Board of Directors of Advanced Medical Technology Association (AdvaMed).

Peter Tippett, MD

Chief Medical Officer, Verizon Communications

Peter Tippett, MD | Chief Medical Officer, Verizon Communications ,

Dr. Tippett is Vice President of The Verizon Incubator and is Verizon’s Chief Medical Officer. He is responsible for Verizon’s healthcare strategy and the development of an extensive portfolio of solutions that enable the rapidly evolving healthcare information technology ecosystem.

Dr. Tippett has worked as an emergency room doctor and as a helicopter emergency physician and carries a California physician and surgeon license. His PhD work included the discovery and modelling of new regulatory mechanisms for glucose by the enzyme glucokinase. He worked for Nobel Laureates Robert Bruce Merrifield (chemistry, 1984) and Stanford Moore (chemistry, 1972) at Rockefeller University where Dr. Tippett was the first person to synthesize an active segment of an immunoglobulin. Earlier, he worked in the Charles Glueck laboratory in Cincinnati where he was one of the first individuals to research and consume “sucrose-octa-ester” (now called Olestra).

Dr. Tippett obtained a BS in biology from Kalamazoo College, and a MD and PhD in biochemistry from Case Western Reserve University. He is board certified in internal medicine.

Pascal Soriot

CEO, AstraZeneca Pharmaceuticals

Pascal Soriot | CEO, AstraZeneca Pharmaceuticals ,

Pascal joined AstraZeneca as an Executive Director and Chief Executive Officer in October 2012. A French national, 53-year-old Pascal joined AstraZeneca from Roche AG where he served as Chief Operating Officer of the company’s pharmaceuticals division since 2010. Prior to that, Pascal was Chief Executive Officer of Genentech, where he was credited with leading the successful merger between the San Francisco-based biologics business and Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior management roles in the US, Asia and Europe.

Why Attend?

The Medical Innovation Summit provides an unrivaled perspective on the newest medical innovations and the financial drivers behind those innovations. The conference is recognized for providing singular insights, networking opportunities and actionable take away for all participants. The content is designed for:

  • Senior executives in the healthcare industry
  • Clinical, medical affairs, regulatory and business development executives
  • Venture capitalists and angel investor groups
  • Investment bankers
  • Buy-side and sell-side researchers
  • Consulting, legal and other service providers

Agenda Highlights

Monday | October 27th
  • New Ventures Healthcare Challenge
  • The State of Healthcare Innovation
  • Dinner and Keynote Address
Tuesday | October 28th
  • Live Surgery
  • The Business of Cancer Diagnostics
  • Imaging and Cancer Detection
  • Networking Recepton
Wednesday | October 29th
  • Therapeutics and Pharmaceuticals
  • Radiation
  • Revealing of the Top 10 Medical Innovations for 2015

2013 Sponsors

View All Past Sponsors

PREMIER
SPONSORS
PLATINUM
SPONSORS